Drugs / ABI-008
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00531271 | Nov 2007 → Dec 2008 | breast cancer | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00477529 | Apr 2007 → Jun 2011 | hormone-resistant prostate carcinoma | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00477529 ↗ |
| Known as | nab-docetaxel | “ABI-008 (nab-docetaxel)” NCT00531271 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT00531271 ↗ |